Chronic Lymphocytic Leukemia

The indication is for adult patients who have received at least 2 prior lines of systemic therapy and is based on the response rate and duration of response shown in a phase 2 trial.

This review discusses the prevalence, mechanisms of development, and evolving treatment landscape in chronic lymphocytic leukemia.

The results demonstrated similar overall survival between patients with chronic lymphocytic leukemia who discontinued specialized follow-ups versus those who continued.

In a phase 1/2 clinical trial, lisocabtagene maraleucel helped patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) achieve complete response rates.

Certain patients may present asymptomatically, affecting treatment options.

Treatment options are distinct in their mechanisms, safety profiles, and implications for patients’ quality of life.

Approximately 41% of enrolled patients responded to NX-2127, and the BTK degrader overcame resistance to nearly all BTK mutations that were identified to cause resistance.

The MRD-guided treatment approach has a significant advantage over chemotherapy.

Presentations detail clinical trial results and focus on drugs in the pipeline.

2023 was an impactful year for the field of oncology pharmacy.

The investigators advise that the use of bendamustine should be avoided when possible in patients with refractory LBCL who are potential candidates for CAR T-cell therapy.

Although treatment is effective, AEs remain difficult for patients.

This is the first trial to show that a measurable residual disease (MRD)–guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of progression-free survival and overall survival.

Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.

Although vaccination status and the severity of COVID-19 infection were not correlated, the timing of vaccine administration influenced whether patients had severe COVID-19 infection.

The acceptance comes after results from TRANSCEND CLL 004, which is the first trial to demonstrate clinical benefit with a CAR T cell therapy in patients who were previously treated for CLL or SLL.

The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.

A low dose of the combination treatment inhibited AML cell cycle and increased apoptosis.

Lisaftoclax is a novel, oral, small-molecule, BCL-2 selective inhibitor being evaluated for treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.

Irreversible Bruton tyrosine kinase inhibitor produces positive results in patients with relapsed/refractory marginal zone lymphoma.

Pirtobrutinib is a non–covalent (reversible) BTK inhibitor, demonstrating a 73.3% overall response rate with a median follow-up of 19.4 months among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In-person visits to receive oral therapy, outpatient infusions, and inpatient infusion for the treatment of hematologic neoplasms declined in the early months of the COVID-19 pandemic, while telemedicine use increased slightly in the same period but remained low overall.

Long-term data show that venetoclax combinations benefit progression free survival and overall survival in patients with or without previous treatment for chronic lymphocytic leukemia.

Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.

Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.

Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.

Since 2014, 10 immunotherapies have been approved by the FDA, including 6 CAR T-cell therapies and 4 BiTE therapies.

CRISPR technology has also been successful in treating a pediatric patient with T-cell acute lymphoblastic leukemia, showing feasibility of its use for cancer immunotherapy.

At 36 months, the overall survival rate of patients with relapsed/refractory B-cell acute lymphoblastic leukemia administered brexucabtagene autoleucel was 47.1%, with a median overall survival of 26 months.